Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Nov;72(5):1096–1101. doi: 10.1038/bjc.1995.471

Induction of p53 protein by gamma radiation in lymphocyte lines from breast cancer and ataxia telangiectasia patients.

G W Birrell 1, J R Ramsay 1
PMCID: PMC2033949  PMID: 7577453

Abstract

Exposure of human cells to gamma-radiation causes levels of the tumour-suppressor nuclear protein p53 to increase in temporal association with the decrease in replicative DNA synthesis. Cells from patients with the radiosensitive and cancer-prone disease ataxia telangiectasia (AT) exhibit radioresistant DNA synthesis and show a reduced or delayed gamma-radiation-induced increase in p53 protein levels. We have used Western immunoblotting with semiquantitative densitometry to examine the gamma-radiation-induced levels of p53 protein in 57 lymphoblastoid cell lines (LCLs) derived from patients with AT, carriers of the AT gene, breast cancer patients and normal donors. We confirm the previously reported reduced induction in AT homozygote LCLs (n = 8) compared with normal donor LCLs (n = 17, P = 0.01). We report that AT heterozygote LCLs (n = 5) also have a significantly reduced p53 induction when compared with LCLs from normal donors (n = 17, P = 0.02). The response of breast cancer patient cells was not significantly different from normal donor cells but 18% (5/27) had a p53 response in the AT heterozygote range (95% confidence interval) compared with only 6% (1/17) of the normal donor cells. We found no significant correlation between p53 induction and cellular radiosensitivity in LCLs from breast cancer patients. These methods may be useful in identifying individuals at greater risk of the DNA-damaging effects of ionising radiation.

Full text

PDF
1096

Images in this article

1098Figure 2
on p.1098

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brachman D. G., Beckett M., Graves D., Haraf D., Vokes E., Weichselbaum R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 1993 Aug 15;53(16):3667–3669. [PubMed] [Google Scholar]
  2. Chen P. C., Lavin M. F., Kidson C., Moss D. Identification of ataxia telangiectasia heterozygotes, a cancer prone population. Nature. 1978 Aug 3;274(5670):484–486. doi: 10.1038/274484a0. [DOI] [PubMed] [Google Scholar]
  3. Easton D. F. Cancer risks in A-T heterozygotes. Int J Radiat Biol. 1994 Dec;66(6 Suppl):S177–S182. doi: 10.1080/09553009414552011. [DOI] [PubMed] [Google Scholar]
  4. Finlay C. A., Hinds P. W., Tan T. H., Eliyahu D., Oren M., Levine A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988 Feb;8(2):531–539. doi: 10.1128/mcb.8.2.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 1993 Feb;8(2):307–318. [PubMed] [Google Scholar]
  6. Houldsworth J., Lavin M. F. Effect of ionizing radiation on DNA synthesis in ataxia telangiectasia cells. Nucleic Acids Res. 1980 Aug 25;8(16):3709–3720. doi: 10.1093/nar/8.16.3709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991 Dec 1;51(23 Pt 1):6304–6311. [PubMed] [Google Scholar]
  8. Kastan M. B., Zhan Q., el-Deiry W. S., Carrier F., Jacks T., Walsh W. V., Plunkett B. S., Vogelstein B., Fornace A. J., Jr A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992 Nov 13;71(4):587–597. doi: 10.1016/0092-8674(92)90593-2. [DOI] [PubMed] [Google Scholar]
  9. Khanna K. K., Lavin M. F. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene. 1993 Dec;8(12):3307–3312. [PubMed] [Google Scholar]
  10. Kuerbitz S. J., Plunkett B. S., Walsh W. V., Kastan M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7491–7495. doi: 10.1073/pnas.89.16.7491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lane D. P. p53 and human cancers. Br Med Bull. 1994 Jul;50(3):582–599. doi: 10.1093/oxfordjournals.bmb.a072911. [DOI] [PubMed] [Google Scholar]
  12. Lavin M. F., Bennett I., Ramsay J., Gardiner R. A., Seymour G. J., Farrell A., Walsh M. Identification of a potentially radiosensitive subgroup among patients with breast cancer. J Natl Cancer Inst. 1994 Nov 2;86(21):1627–1634. doi: 10.1093/jnci/86.21.1627. [DOI] [PubMed] [Google Scholar]
  13. Lavin M. F., Le Poidevin P., Bates P. Enhanced levels of radiation-induced G2 phase delay in ataxia telangiectasia heterozygotes. Cancer Genet Cytogenet. 1992 Jun;60(2):183–187. doi: 10.1016/0165-4608(92)90014-y. [DOI] [PubMed] [Google Scholar]
  14. Liu M., Dhanwada K. R., Birt D. F., Hecht S., Pelling J. C. Increase in p53 protein half-life in mouse keratinocytes following UV-B irradiation. Carcinogenesis. 1994 Jun;15(6):1089–1092. doi: 10.1093/carcin/15.6.1089. [DOI] [PubMed] [Google Scholar]
  15. McIlwrath A. J., Vasey P. A., Ross G. M., Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 1994 Jul 15;54(14):3718–3722. [PubMed] [Google Scholar]
  16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  17. Nagasawa H., Little J. B. Comparison of kinetics of X-ray-induced cell killing in normal, ataxia telangiectasia and hereditary retinoblastoma fibroblasts. Mutat Res. 1983 May;109(2):297–308. doi: 10.1016/0027-5107(83)90054-4. [DOI] [PubMed] [Google Scholar]
  18. Nasrin N., Kunhi M., Einspenner M., al-Sedairy S., Hannan M. Reduced induction of P53 protein by gamma-irradiation in ataxia telangiectasia cells without constitutional mutations in exons 5, 6, 7, and 8 of the p53 gene. Cancer Genet Cytogenet. 1994 Oct;77(1):14–18. doi: 10.1016/0165-4608(94)90142-2. [DOI] [PubMed] [Google Scholar]
  19. Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet. 1986 Aug;73(4):320–326. doi: 10.1007/BF00279094. [DOI] [PubMed] [Google Scholar]
  20. Nelson W. G., Kastan M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol. 1994 Mar;14(3):1815–1823. doi: 10.1128/mcb.14.3.1815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Oren M., Maltzman W., Levine A. J. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol. 1981 Feb;1(2):101–110. doi: 10.1128/mcb.1.2.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Parshad R., Sanford K. K., Jones G. M., Tarone R. E. G2 chromosomal radiosensitivity of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet. 1985 Jan 1;14(1-2):163–168. doi: 10.1016/0165-4608(85)90227-4. [DOI] [PubMed] [Google Scholar]
  23. Peterson R. D., Funkhouser J. D., Tuck-Muller C. M., Gatti R. A. Cancer susceptibility in ataxia-telangiectasia. Leukemia. 1992;6 (Suppl 1):8–13. [PubMed] [Google Scholar]
  24. Ramsay J., Birrell G. Normal tissue radiosensitivity in breast cancer patients. Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):339–344. doi: 10.1016/0360-3016(94)00478-4. [DOI] [PubMed] [Google Scholar]
  25. Scott D., Spreadborough A., Levine E., Roberts S. A. Genetic predisposition in breast cancer. Lancet. 1994 Nov 19;344(8934):1444–1444. doi: 10.1016/s0140-6736(94)90615-7. [DOI] [PubMed] [Google Scholar]
  26. Swift M., Chase C. L., Morrell D. Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet. 1990 May;46(1):21–27. doi: 10.1016/0165-4608(90)90004-t. [DOI] [PubMed] [Google Scholar]
  27. Swift M. Ionizing radiation, breast cancer, and ataxia-telangiectasia. J Natl Cancer Inst. 1994 Nov 2;86(21):1571–1572. doi: 10.1093/jnci/86.21.1571. [DOI] [PubMed] [Google Scholar]
  28. Swift M., Morrell D., Massey R. B., Chase C. L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991 Dec 26;325(26):1831–1836. doi: 10.1056/NEJM199112263252602. [DOI] [PubMed] [Google Scholar]
  29. Ullrich S. J., Anderson C. W., Mercer W. E., Appella E. The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem. 1992 Aug 5;267(22):15259–15262. [PubMed] [Google Scholar]
  30. Weeks D. E., Paterson M. C., Lange K., Andrais B., Davis R. C., Yoder F., Gatti R. A. Assessment of chronic gamma radiosensitivity as an in vitro assay for heterozygote identification of ataxia-telangiectasia. Radiat Res. 1991 Oct;128(1):90–99. [PubMed] [Google Scholar]
  31. Weinert T. A., Hartwell L. H. The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science. 1988 Jul 15;241(4863):317–322. doi: 10.1126/science.3291120. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES